OKYO Pharma Limited (OKYO) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in London, United Kingdom. The current CEO is Robert J. Dempsey.
OKYO has IPO date of 2022-05-17, 3 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $63.31M.
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
